Literature DB >> 11463385

Structural model for the cooperative assembly of HIV-1 Rev multimers on the RRE as deduced from analysis of assembly-defective mutants.

C Jain1, J G Belasco.   

Abstract

The functional efficacy of the HIV-1 Rev protein is highly dependent on its ability to assemble onto its HIV-1 RNA target (the RRE) as a multimeric complex. To elucidate the mechanism of multimeric assembly, we have devised two rapid and broadly applicable strategies for examining cooperative interactions between proteins bound to RNA, one based on cooperative translational repression of a two-site reporter and the other on gel shift analysis with crude E. coli extracts. Using these strategies, we have identified two distinct surfaces of Rev (head and tail) that are critical for different steps in multimeric assembly. Our data indicate that Rev assembles cooperatively on the RRE via a series of symmetrical tail-to-tail and head-to-head protein-protein interactions. The insights into molecular architecture suggested by these findings have enabled us to derive a structural model for Rev and its multimerization on the RRE.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11463385     DOI: 10.1016/s1097-2765(01)00207-6

Source DB:  PubMed          Journal:  Mol Cell        ISSN: 1097-2765            Impact factor:   17.970


  51 in total

1.  Implications of the HIV-1 Rev dimer structure at 3.2 A resolution for multimeric binding to the Rev response element.

Authors:  Michael A DiMattia; Norman R Watts; Stephen J Stahl; Christoph Rader; Paul T Wingfield; David I Stuart; Alasdair C Steven; Jonathan M Grimes
Journal:  Proc Natl Acad Sci U S A       Date:  2010-03-15       Impact factor: 11.205

2.  HIV Rev response element (RRE) directs assembly of the Rev homooligomer into discrete asymmetric complexes.

Authors:  Matthew D Daugherty; David S Booth; Bhargavi Jayaraman; Yifan Cheng; Alan D Frankel
Journal:  Proc Natl Acad Sci U S A       Date:  2010-06-28       Impact factor: 11.205

Review 3.  No longer a nuisance: long non-coding RNAs join CENP-A in epigenetic centromere regulation.

Authors:  Silvana Rošić; Sylvia Erhardt
Journal:  Cell Mol Life Sci       Date:  2016-01-09       Impact factor: 9.261

4.  Single-nucleotide changes in the HIV Rev-response element mediate resistance to compounds that inhibit Rev function.

Authors:  Deidra Shuck-Lee; Hua Chang; Emily A Sloan; Marie-Louise Hammarskjold; David Rekosh
Journal:  J Virol       Date:  2011-02-02       Impact factor: 5.103

5.  RNA-binding protein RBMS3 is expressed in activated hepatic stellate cells and liver fibrosis and increases expression of transcription factor Prx1.

Authors:  Dillon Fritz; Branko Stefanovic
Journal:  J Mol Biol       Date:  2007-06-09       Impact factor: 5.469

6.  HIV-1 Rev protein assembles on viral RNA one molecule at a time.

Authors:  Stephanie J K Pond; William K Ridgeway; Rae Robertson; Jun Wang; David P Millar
Journal:  Proc Natl Acad Sci U S A       Date:  2009-01-21       Impact factor: 11.205

7.  The arginine-rich RNA-binding motif of HIV-1 Rev is intrinsically disordered and folds upon RRE binding.

Authors:  Fabio Casu; Brendan M Duggan; Mirko Hennig
Journal:  Biophys J       Date:  2013-08-20       Impact factor: 4.033

8.  A DEAD-Box Helicase Mediates an RNA Structural Transition in the HIV-1 Rev Response Element.

Authors:  John A Hammond; Rajan Lamichhane; David P Millar; James R Williamson
Journal:  J Mol Biol       Date:  2017-01-31       Impact factor: 5.469

9.  Resistance to RevM10 inhibition reflects a conformational switch in the HIV-1 Rev response element.

Authors:  Michal Legiewicz; Christopher S Badorrek; Kevin B Turner; Daniele Fabris; Tiffany E Hamm; David Rekosh; Marie-Louise Hammarskjöld; Stuart F J Le Grice
Journal:  Proc Natl Acad Sci U S A       Date:  2008-09-05       Impact factor: 11.205

10.  Rapid and efficient purification of RNA-binding proteins: application to HIV-1 Rev.

Authors:  Marco Marenchino; David W Armbruster; Mirko Hennig
Journal:  Protein Expr Purif       Date:  2008-09-25       Impact factor: 1.650

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.